Welcome to the new Trendletter, a quarterly publication of The Trendlines Group. We will be writing about subjects of interest to those who invest in Israeli companies and those who are now considering their first steps toward investing in Israel. We will also feature observations and opinions from other investors and market watchers. Within the realm of Israeli investing, we highlight seed and early-stage companies, Trendlines' principal field of investment focus and business development work. Our business - our mission - is the creation and development of businesses to improve the human condition; this, too, will be reflected in the Trendletter.
This newsletter completes the four newsletters of The Trendlines Group. Our Misgav and Mofet incubators each publish a quarterly newsletter about their activities and their portfolio companies; our business development arm, Signal Business Development, publishes SignalPoint, a monthly newsletter about Israel-focused business development and marketing matters.
Let us hear from you. We'd like your feedback. Tell us what you'd like to read more about.
D. Todd Dollinger, Chairman and CEO Steve Rhodes, Chairman and CEO |
|
|
D. Todd Dollinger Assesses 2010 as "Execution-Focused"Early last year, I wrote to Trendlines' investors that 2009 was to be an "investment-focused" year for Trendlines. While companies' values were depressed worldwide, our companies did well. With a single exception, every one of our portfolio companies that raised funds in 2009 did so at a value higher than in their prior rounds - this has continued to be the case this year. As 2009 was "investment-focused," 2010 is very much "execution-focused," with major emphasis on getting our portfolio companies before investors and, in select cases, in front of potential acquirers. Because life sciences companies represent the largest part of Trendlines' value, market changes, the investment atmosphere, and regulatory matters are all issues to which we pay great attention. For more on these matters, see the Mergermarket Group's " Life Sciences & Healthcare Sector Forecast," sponsored by our friends at Epstein, Becker, Green and Rodman and Renshaw. It's interesting reading; among the conclusions: "... a desire for new products and technologies will outweigh health care reform as the primary driver of M&A activity among biotechnology and pharmaceuticals companies and among medical device manufacturers and suppliers..."The Trendlines Group Closes $7.5 Million Raise The Trendlines Group Closes $8 Million Raise
Trendlines current shareholders and new investors have invested an additional $8 million in the Group for a total of $14 million over three years. Funds will be used to expand the Group's core activities of creating and developing business that improve the human condition as well as in the development of special investment opportunities. |
Misgav Named Incubator of the Year |
Steve Rhodes, Trendlines CEO and Chairman, Accepts 2009 Incubator of the Year Award |
The Misgav Venture Accelerator was named "Best Incubator" at the Office of the Chief Scientist's annual incubator awards program. The program recognizes Israel's outstanding incubator and best companies. In addition to Misgav being named Best Incubator, Misgav company Virtual Ports was a finalist in the Best Company competition. After accepting the award, Misgav CEO Dr. Eran Feldhay noted, "This award is a testament to our commitment to and our successes in creating and developing business to improve the human condition. We are proud to have created an environment where entrepreneurs can learn, share, develop, and grow their businesses." "We are absolutely thrilled to win this prestigious award. It is a credit to everyone who works at the Misgav Venture Accelerator and to our companies," said Steve Rhodes, co-CEO of The Trendlines Group, which owns the Misgav Venture Accelerator. Udi Gordin, CEO of Best Company finalist Virtual Ports, commented: "It is always the highest compliment when an industry recognizes one of its own. We greatly appreciate all the help and support we receive from all the professionals at Trendlines and Misgav. It has made a big difference for us." Read the Globes business newspaper coverage (in Hebrew) |
News from the Trendlines Portfolio |
Otomedics' next generation tympanostomy tube - U-tube - was presented in Las Vegas at COSM, the otolaryngology spring meeting. Otomedics' U-tube, an implant developed for treating ear infections, attracted considerable interest. From early 2010, Otomedics has been selling in the U.S. During the first half of 2010, the Trendlines Group's incubators, Misgav and Mofet, established 4 new companies: MagDent is developing processes for improving and enhancing the absorption of dental implants, shortening the treatment period by enhancing bone density around the implant and the recovery of tissues. Liola Technologies' operational optimization software for complicated, multi-variables manufacturing systems connects between MES and ERP systems, automatically learns processes and events, analyses them, and produces operational plans based on simulation and optimization. This software is an essential tool for operations management and analysis for critical decision making and implementation for organizations with long, complex and expensive manufacturing processes, such as the semiconductor industry.
Leviticus Cardio's ventricular assist device for congestive heart failure, enables treating critical or elderly patients who are not candidates for open heart surgery due to age or medical condition.
MediValve is developing a replacement aortic valve and positioning device that will give interventional cardiologists complete control for correct valve location. The positioning device will be adaptable for use with all aortic valves. |
| ETView and FlowSense Publicly Traded on TASE |
Trendlines portfolio companies ETView and FlowSense are now traded on the Tel Aviv Stock Exchange. Todd Dollinger, Trendlines' Chairman and CEO, serves as chairman of both companies. ETView, developer of the tracheoscopic ventilation tube (TVT) with an embedded video camera, listed on the TASE under the symbol "ETVW" in July. FlowSense, producer of automatic urine flow monitoring systems, began trading on the TASE in August under the temporary symbol "DOROT." |
| Financings |
HTL closed $250,000 as part of a $2 million round that the company expects to complete in the coming months. The raise enables the company to complete development of its first product which has been contracted for distribution by a large European pharma company. HTL was founded by leaders in the clinical nutrition field who recognized the importance of improved lipid emulsions for more effective total parenteral nutrition.
JetGuide closed a $320,000 private investment that will bring its device for bone drilling guidance to beta testing and FDA clearance. CEO Dr. Jacob Halevy-Politch announced that the company's U.S. patent was issued for a "novel ultrasonic device used to access vital structures in implant." Nephera raised $2.85 million from Israeli VCs Aurum and Evergreen, and The Trendlines Group, The company is developing a novel device for improving renal function in congestive heart failure patients. |
| Thank You to Dr. Reuven Regev |
Dr. Reuven Regev joined the Misgav Venture Accelerator in 1992 as the first chairman of the board when Misgav was established to support in national effort to absorb the large wave of immigrants from the former Soviet Union. Through the incubator's transformations, Reuven has been instrumental as an advisor, mentor, teacher, and friend, helping to guide the incubator. A large measure of thanks is due to Reuven who recently left the Misgav board. He continues as chairman of Trendlines portfolio company Flexicath. |
|
|
- Expectations regarding market improvements begin to decline
- Forecasts of new investments reflect cautious optimism
- Increasing optimism geared towards 2010 as the year to unfold as Israel's first IPO on NASDAQ
- Geopolitical issues raise concerns among venture capitalists
- The Finance Ministry should focus on encouraging:
- Seed investments
- Israeli institutions to take a larger role in high-tech investments
All About Israeli Innovation
Watch the You Tube clip about Israeli innovation for a reminder about how much has been accomplished in 60+ years and how much potential is still waiting to be exploited. Thanks to Lesley Portnoy of New York-based law firm Baker Hostetler for this. |
|
|
The Organization for Economic Cooperation and Development, which groups the world's most developed economies, accepted Israel for membership. "This is an important step towards Israel's integration into the global economy," said Governor of the Bank of Israel, Stanley Fischer. Read more. |
|
|
|
|
|
Trendlines Staff |
Dr. Eran Feldhay has been appointed CEO of the Misgav Venture Accelerator. Eran spent 12 years at Medcon Systems, a McKesson company where he began as a product manager and moved through various product, marketing, and management positions, serving as Medcon's general manager from 2006. He is a director of TASE-traded TopSpin Medical. Eran earned a B.Sc. and an M.D. from Tel Aviv University.
Gabi Heller has joined The Trendlines Group in the position of CFO. She has extensive financial experience as an accountant, CFO, and as a director of public companies. Gabi served as CFO of Walden Israel Venture Capital for 16 years and, prior to that, as a manager at Ernst & Young. She is a CPA with a BA in economics and accounting from the Hebrew University of Jerusalem and holds an LLM degree from Bar Ilan University.
Ronen Koyfman has moved from Trendlines CFO to the newly-created position of Consulting CFO, where he serves as CFO of our publicly traded portfolio companies, ETView and FlowSense, and handles strategic projects for The Trendlines Group.
Robert Bash was named CEO of Flowsense. He comes to Flowsense with an impressive record of success in the medical device field, having successfully launched and sold YMed, Inc. Prior to that, Robert spent nine years in venture capital management as a partner at Infinity Venture Capital (Tel Aviv/New York). Robert has a B.A. from the University of Pennsylvania, a J.D. from Georgetown University, and an LL.M. from New York University.
|
|
|